Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $78.56 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 42.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,274 shares of the biopharmaceutical company's stock after purchasing an additional 25,828 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned approximately 0.08% of Regeneron Pharmaceuticals worth $78,561,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. West Paces Advisors Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 23 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth $26,000. Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $31,000. MCF Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 12 shares in the last quarter. Finally, Criterion Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $37,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 3.8 %

NASDAQ:REGN traded up $34.13 on Thursday, hitting $937.61. The stock had a trading volume of 1,066,779 shares, compared to its average volume of 499,355. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a market cap of $102.91 billion, a P/E ratio of 26.98, a price-to-earnings-growth ratio of 2.55 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The firm's fifty day simple moving average is $944.24 and its two-hundred day simple moving average is $895.54.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same quarter last year, the business posted $10.96 EPS. Regeneron Pharmaceuticals's quarterly revenue was up .6% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the firm's stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares of the company's stock, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Arthur F. Ryan sold 100 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares of the company's stock, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares of the company's stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold a total of 10,095 shares of company stock worth $9,664,476 in the last quarter. Insiders own 8.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on REGN shares. Bank of America increased their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an "underperform" rating in a report on Friday, April 12th. Cantor Fitzgerald restated a "neutral" rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. StockNews.com downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an "outperform" rating in a report on Monday, February 5th. Finally, Truist Financial restated a "buy" rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $977.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.